Using a special material to boost immune responses against triple negative breast cancer
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
This study is testing a new way to boost your immune system against triple negative breast cancer by using a special material injected during surgery, which helps your body fight the cancer more effectively right from the start.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Symphony Biosciences, INC. NIH-funded |
| Lab location | 1 site (Santa Monica, United States) |
| Project ID | NIH-11174056 on NIH RePORTER |
What this research studies
This research focuses on enhancing the body's immune response to triple negative breast cancer by using a unique biomaterial. The approach involves injecting a synthetic scaffold at the time of surgery or biopsy, which helps to activate local immune cells and suppress those that inhibit immune responses. By starting treatment immediately during surgery, the goal is to improve the effectiveness of the immune system in fighting solid tumors. This innovative method aims to address the challenges faced by current immunotherapies for solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are scheduled for surgery.
Not a fit: Patients with non-solid tumors or those who are not undergoing surgical treatment for their cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: While there have been advancements in immunotherapies for hematopoietic cancers, this approach for solid tumors is relatively novel and has not been extensively tested.
Where this research is happening
Santa Monica, United States
- Symphony Biosciences, INC. — Santa Monica, United States (Active)
Researchers
- Principal investigator: Erfan, Dashtimoghadam — Symphony Biosciences, INC.
- Study coordinator: Erfan, Dashtimoghadam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.